https://www.selleckchem.com/pr....oducts/edralbrutinib
To identify underlying subgroups with distinct symptom profiles, and to characterise and compare these subgroups across a range of demographic, clinical and psychosocial factors, within a heterogeneous group of patients with well-defined post-treatment Lyme disease (PTLD). A clinical case series of patents. Participants were recruited from a single-site, Lyme disease referral clinic patient population and were evaluated by physical exam, clinical laboratory testing and standardised questionnaires. Two hundred and twelve participan
Like
Comment
Share
